	Beneficio Bruto En Ventas		Fecha
AbbVie	USD 10.47B	605M	2025-09
Acadia Pharmaceuticals	USD 257.76M	778K	2025-12
Akebia Therapeutics	USD 49.21M	13.25M	2025-03
ALKERMES	USD 338.34M	72.51M	2025-12
Alnylam Pharmaceuticals	USD 829.31M	219.56M	2025-12
Amarin	USD 22.21M	28.15M	2025-09
Amgen	USD 6.48B	307M	2025-09
Baxter International	USD 577M	373M	2025-12
Biogen	USD 1.65B	34.6M	2025-12
BioMarin Pharmaceutical	USD 713.01M	81.81M	2025-12
Bristol-Myers Squibb	USD 8.79B	110M	2025-09
Coherus Biosciences	USD 4.95M	15.34M	2025-03
Eli Lilly	USD 14.59B	1.48B	2025-09
Fujifilm	JPY 347.51B	14.74B	2025-12
Gilead Sciences	USD 6.31B	106M	2025-12
Ironwood Pharmaceuticals	USD 85.24M	44.1M	2025-06
Merck	USD 13.42B	431M	2025-09
Myriad Genetics	USD 143.8M	8M	2025-09
Pacira	USD 142.25M	11.34M	2025-12
Perrigo	USD 362.2M	14.9M	2025-12
Pfizer	USD 3.54B	7.61B	2025-09
PTC Therapeutics	USD 148.38M	39.31M	2025-12
Regeneron Pharmaceuticals	USD 3.3B	67M	2025-12
Sarepta Therapeutics	USD 43.55M	204.36M	2025-12
Teva Pharmaceutical Industries	USD 2.66B	351M	2025-12
Vertex Pharmaceuticals	USD 2.72B	62.4M	2025-12
Xencor	USD 21M	22.61M	2025-09
Zoetis	USD 1.64B	73M	2025-12

Coherus Biosciences Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.